Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)

Avalo Therapeutics (AVTX) has disclosed Equity Income for 2 consecutive years, with -$1.9 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Equity Income changed N/A year-over-year to -$1.9 million, compared with a TTM value of -$1.9 million through Mar 2021, down 126.24%, and an annual FY2020 reading of $5.2 million, up 9556.6% over the prior year.
  • Equity Income was -$1.9 million for Q2 2020 at Avalo Therapeutics, down from $7.1 million in the prior quarter.
  • Across five years, Equity Income topped out at $7.1 million in Q1 2020 and bottomed at -$1.9 million in Q2 2020.